ClinicalTrials.gg
TerminatedNCT03941834Updated Jun 10, 2024Results posted

Trial for Treatment Refractory Trigeminal Neuralgia

A Phase 2 interventional study of Rimegepant and Placebo in Trigeminal Neuralgia, sponsored by Pfizer. Terminated at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-10.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Why this study was terminated
Strategic decision to discontinue the study based on adjusted clinical development plan. This decision is not based on any safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in Trigeminal Neuralgia with a site in United States — 7 open to participants now, 11 under way, 1 of them phase 3. Trigeminal Neuralgia · United States.

Enrollment
3rd of 26
65 · median 29
Started
2019
with 2 others
Phase 2
5 of 34
none open now
Registered
21st of 34
by date

Among the 34 studies in Trigeminal Neuralgia with a site in United States, this one is the 3rd largest by enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2019, is one of 5 in phase 2, and was the 21st registered.

Trigeminal Neuralgia

140 studies on the registry are indexed under Trigeminal Neuralgia; 44 are open to participants now.

Browse Trigeminal Neuralgia studies →

Open to participants now

7 of the 34 studies in Trigeminal Neuralgia with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 27 Trigeminal Neuralgia studies recruiting now, 18 (67%) set no upper age limit and 3 (11%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Trigeminal Neuralgia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of BHV3000 compared to placebo for subjects with treatment refractory Trigeminal Neuralgia as measured by a 2-point or greater reduction in the average Numeric Pain Rating Scale between the two-week treatment phases.

03

Conditions studied

  • Trigeminal Neuralgia

Keywords

  • Trigeminal Neuralgia, Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects with a clinical diagnosis of typical or atypical classical trigeminal neuralgia based on the International Classification of Headache Disorders, 3rd edition, beta version.
  2. Trigeminal neuralgia symptoms for a minimum of 8 weeks prior to randomization visit.
  3. Neuroimaging to exclude another cause for the neuralgia, other than neurovascular compression.

Exclusion criteria

Exclusion Criteria:

  1. Subject has a structural lesion on neuroimaging, other than vascular compression of the trigeminal nerve or nerve root that would explain the neuralgia
  2. Subject has a clinically evident neurologic deficit on neurologic exam of the cranial nerves
  3. Subjects with a history of disease
  4. Subject history with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia. Subjects with Myocardial Infarction (MI), Acute Coronary Syndrome (ACS), Percutaneous Coronary Intervention (PCI), cardiac surgery, stroke or (TIA) during the 6 months prior to screening
  5. Uncontrolled hypertension (high blood pressure) at screening
  6. Subject has a current diagnosis of major depression, other pain syndromes, psychiatric conditions (e.g., schizophrenia), dementia, or significant neurological disorders (other than migraine) that, in the Investigator's opinion, might interfere with study assessments
  7. Subject has a history of gastric, or small intestinal surgery (including Gastric Bypass, Gastric Banding, Gastric Sleeve, Gastric Balloon, etc.), or has a disease that causes malabsorption
  8. Subject has a history or diagnosis of Gilbert's Syndrome or any other active hepatic or biliary disorder
  9. The subject has a history or current evidence of any significant and/or unstable medical conditions (e.g., history of congenital heart disease or arrhythmia, known suspected infection, or C, or cancer) that, in the investigator's opinion, would expose them to undue risk of a significant adverse event (AE) or interfere with assessments of safety or efficacy during the course of the trial
  10. History of, treatment for, or evidence of, alcohol or drug abuse within the past 12 months or subjects who have met criteria for any significant substance use disorder within the past 12 months from the date of the screening visit
  11. Hematologic or solid diagnosis within 5 years prior to screening. Subjects with a history of localized basal cell or squamous cell skin cancer are eligible for the study if they are cancer-free prior to the screening visit in this study.
  12. Hematologic or solid malignancy diagnosis within 5 years prior to screening. Subjects with a history of localized basal cell or squamous cell skin cancer are eligible for the study if they are cancer-free prior to the screening visit in this study.
  13. >33kg/m²
  14. History of gallstones or cholecystectomy
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
65 participants (actual)

Study arms

  • Active comparator
    BHV3000

    Drug: Rimegepant

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • BHV3000 (rimegepant) 75mg tablet

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Average Daily Pain Score on Numeric Pain Rating Scale (NPRS) at 2 Week Treatment Phase: DBT Phase

    NPRS is an 11-point scale ranging from 0 (no pain) to 10 (worst pain imaginable), higher scores represent worse pain. Participants daily recorded their average pain level over a 24-hour period on NPRS. Pain score was the average of the daily 11-point NPRS recorded within each period. Average of pain score on NPRS according to treatment received in first or second treatment period of DBT phase are used for evaluation of the outcome measure.

    Time frame: DBT Phase: Baseline (before dose on Day 1), 2 Weeks Treatment

Secondary outcomes

  1. Number of Participants With All-Causality Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Study Drug Discontinuation and Treatment Related AEs: DBT Phase

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship with the study treatment. SAE: Any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect other important medical events. A treatment-related AE was any untoward medical occurrence attributed to the study drug in a participant who received study drug. Relatedness to drug was assessed by investigator.

    Time frame: DBT Phase: Day 1 of dosing up to last day of dosing (up to 5 weeks)

  2. Number of Participants With Any Change From Baseline in Sheehan Suicidality Tracking Scale (S-STS) Scores: DBT Phase

    S-STS is a scale that assesses the seriousness of suicidality phenomena on a 5-point Likert-type scale (0 to 4) ranging from "not at all" (0) to "extremely" (4), where higher scores signify suicidal tendency. In this outcome measure, number of participants who had any change in S-STS score from baseline to end of treatment are reported according to the treatment received in first or second treatment period of DBT phase.

    Time frame: DBT Phase: Baseline, 2 Weeks Treatment

  3. Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities: DBT Phase

    ECG abnormalities included were a Corrected QT interval exceeding 470 milliseconds (QTc calculated using the Frederica method), left bundle branch block, right bundle branch block with a QRS duration of 150 milliseconds or more, and intraventricular conduction defect with a QRS duration equal to or greater than 150 milliseconds. Clinical significance in ECG abnormalities was judged by investigator.

    Time frame: DBT Phase: Day 1 of dosing up to last day of dosing (up to 5 weeks)

  4. Number of Participants With Clinically Significant Laboratory Abnormalities: DBT Phase

    Laboratory abnormalities included 1)Hematology: hemoglobin, hematocrit, platelets, complete blood count with differential and absolute neutrophil count; 2)Serum chemistry: sodium, potassium, chloride, calcium, alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, alkaline phosphatase, gamma-glutamyl transferase, phosphorus, bicarbonate, creatine phosphokinase, total protein, albumin, total bilirubin, glucose, creatinine, blood urea nitrogen, uric acid, total cholesterol, low-density lipoprotein, high-density lipoprotein, triglycerides, folate, hemoglobin A1C, pancreatic amylase or lipase, thyroid-stimulating Hormone, thyroxine; 3)Urinalysis: macroscopic examination, pH, specific gravity, ketones, nitrites, urobilinogen, leukocyte esterase, protein, glucose, occult blood; 4)Liver function tests: alanine aminotransferase, aspartate aminotransferase, total bilirubin, alkaline phosphatase. Clinical significance in laboratory abnormalities was judged by investigator.

    Time frame: DBT Phase: Day 1 of dosing up to last day of dosing (up to 5 weeks)

  5. Change From Baseline in Penn Facial Pain Scale-Revised (Penn-FPS-R) Total Score at 2 Week Treatment Phase: DBT Phase

    Penn-FPS-R: a 12-item scale, utilized to evaluate the impact of TN pain on health-related quality of life and daily activities. Each 12 items ranged from 0 (does not interfere) to 10 (completely interferes). Penn-FPS-R total score was calculated by adding scores of all items and had a score range of (does not interfere) 0 to 120 (completely interferes).Higher Penn-FPS-R total scores signifies worse condition. Participants were asked to complete the Penn-FPS-R at the beginning and end of each treatment period. Average of total Penn-FPS-score according to treatment received in first or second treatment period of DBT phase are used in evaluation of the outcome measure.

    Time frame: DBT Phase: Baseline, 2 Weeks Treatment

  6. Change From Baseline in Pain Disability Index Total Score at 2 Week Treatment Phase: DBT Phase

    Pain disability index measures the extent of disruption in a participant's daily life caused by pain, utilizing a 7-item scale scored on an 11-point Likert Scale, where "0" denotes "no disability," and "10" indicates "worst disability". Higher scores signify worse outcome. Pain disability index total score was calculated by adding scores of all the 7 items and had a score range of 0 to 70. Higher pain disability index total scores signifies worse condition. Participants were instructed to complete the pain disability index at the beginning and end of each treatment period. Average of pain disability index total scores according to treatment received in first or second treatment period of DBT phase are used for evaluation of the outcome measure.

    Time frame: DBT Phase: Baseline, 2 Weeks Treatment

  7. Patient Global Impression of Change Scale (PGI-C) Score at 2 Week Treatment Phase: DBT Phase

    PGI-C is a participant-reported scale utilized to evaluate the improvement or deterioration of the participant's current illness status compared to the baseline visit. Participants were asked to rate a change in their overall disease condition on a 7-point scale, ranging from 1 (no change) to 7 (a great deal better). Higher PGI-C scores signify better outcome. PGI-C assessments were conducted at the beginning and end of each treatment phase. Average of PGI-C score according to treatment received in first or second treatment period of DBT phase are used in evaluation of the outcome measure.

    Time frame: DBT Phase: Baseline, 2 Weeks Treatment

  8. Change From Baseline in Average Worst Pain Score on NPRS at 2 Week Treatment Phase: DBT Phase

    NPRS is an 11-point scale ranging from 0 (no pain) to 10 (worst pain imaginable), higher scores represent worse pain. Participants daily recorded their worst pain rating over a 24-hour period on NPRS. Average of worst pain NPRS score according to treatment received in first or second treatment period of DBT phase are used in evaluation of the outcome measure.

    Time frame: DBT Phase: Baseline, 2 Weeks Treatment

  9. Percentage of Participants With >= 2 Point Reduction From Baseline in Average Daily Pain Score on NPRS at 2 Week Treatment Phase: DBT Phase

    NPRS is an 11-point scale ranging from 0 (no pain) to 10 (worst pain imaginable), higher scores represent worse pain. Participants daily recorded their average pain level over a 24-hour period. Pain score was the average of the daily 11-point NPRS recorded within each period. Average of pain score on NPRS according to treatment received in first or second treatment period of DBT Phase are used in evaluation of the outcome measure.

    Time frame: DBT Phase: Baseline, 2 Weeks Treatment

07

Results

Posted Jun 10, 2024

Participant flow

There were 2 phases in the study: double blind treatment (DBT) phase followed by open label extension (OLE) phase. Participants after completing DBT phase could enter OLE phase if the Principal Investigator (PI) believed open-label treatment offered an acceptable risk-benefit profile. A total of 65 participants with refractory trigeminal neuralgia (TN) were enrolled in the study.

DBT Phase: 1st Treatment Period (2Weeks)
Participant flow — DBT Phase: 1st Treatment Period (2Weeks)
MilestoneDBT Phase: Placebo Then Rimegepant (BHV-3000)DBT Phase: Rimegepant Then PlaceboOLE Phase: Rimegepant
Started15150
Treated15140
Completed14140
Not completed110
Withdrew: Randomized but not treated010
Withdrew: Non compliance100
DBT Phase: Washout Period (7 Days)
Participant flow — DBT Phase: Washout Period (7 Days)
MilestoneDBT Phase: Placebo Then Rimegepant (BHV-3000)DBT Phase: Rimegepant Then PlaceboOLE Phase: Rimegepant
Started14140
Completed14140
Not completed000
2nd Treatment Period (2Weeks)
Participant flow — 2nd Treatment Period (2Weeks)
MilestoneDBT Phase: Placebo Then Rimegepant (BHV-3000)DBT Phase: Rimegepant Then PlaceboOLE Phase: Rimegepant
Started14140
Completed14140
Not completed000
OLE Phase (12 Weeks)
Participant flow — OLE Phase (12 Weeks)
MilestoneDBT Phase: Placebo Then Rimegepant (BHV-3000)DBT Phase: Rimegepant Then PlaceboOLE Phase: Rimegepant
Started0013
Completed009
Not completed004
Withdrew: Study terminated by sponsor001
Withdrew: Lack of efficacy001
Withdrew: Sponsor decision001
Withdrew: Withdrawal by subject001

Outcome measures

PrimaryChange From Baseline in the Average Daily Pain Score on Numeric Pain Rating Scale (NPRS) at 2 Week Treatment Phase: DBT Phase

NPRS is an 11-point scale ranging from 0 (no pain) to 10 (worst pain imaginable), higher scores represent worse pain. Participants daily recorded their average pain level over a 24-hour period on NPRS. Pain score was the average of the daily 11-point NPRS recorded within each period. Average of pain score on NPRS according to treatment received in first or second treatment period of DBT phase are used for evaluation of the outcome measure.

Time frame:
DBT Phase: Baseline (before dose on Day 1), 2 Weeks Treatment
Reported as:
Least squares mean · Units on a scale
Change From Baseline in the Average Daily Pain Score on Numeric Pain Rating Scale (NPRS) at 2 Week Treatment Phase: DBT Phase
Units on a scaleDBT Phase: Pooled RimegepantDBT Phase: Pooled Placebo
Change From Baseline in the Average Daily Pain Score on Numeric Pain Rating Scale (NPRS) at 2 Week Treatment Phase: DBT Phase-.5 (-1.1 to -.1)-1.2 (-1.8 to -0.6)
Statistical analysis
  • DBT Phase: Pooled Rimegepant vs DBT Phase: Pooled Placebo · Least square (ls) mean difference: 0.7 · 95% CI 0.1 to 1.2
SecondaryNumber of Participants With All-Causality Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Study Drug Discontinuation and Treatment Related AEs: DBT Phase

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship with the study treatment. SAE: Any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect other important medical events. A treatment-related AE was any untoward medical occurrence attributed to the study drug in a participant who received study drug. Relatedness to drug was assessed by investigator.

Time frame:
DBT Phase: Day 1 of dosing up to last day of dosing (up to 5 weeks)
Reported as:
Count of participants · Participants
Number of Participants With All-Causality Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Study Drug Discontinuation and Treatment Related AEs: DBT Phase
ParticipantsDBT Phase: Pooled RimegepantDBT Phase: Pooled Placebo
SAEs00
AEs Leading to Study Drug Discontinuation00
Treatment Related AEs40
SecondaryNumber of Participants With Any Change From Baseline in Sheehan Suicidality Tracking Scale (S-STS) Scores: DBT Phase

S-STS is a scale that assesses the seriousness of suicidality phenomena on a 5-point Likert-type scale (0 to 4) ranging from "not at all" (0) to "extremely" (4), where higher scores signify suicidal tendency. In this outcome measure, number of participants who had any change in S-STS score from baseline to end of treatment are reported according to the treatment received in first or second treatment period of DBT phase.

Time frame:
DBT Phase: Baseline, 2 Weeks Treatment
Reported as:
Count of participants · Participants
Number of Participants With Any Change From Baseline in Sheehan Suicidality Tracking Scale (S-STS) Scores: DBT Phase
ParticipantsDBT Phase: Pooled RimegepantDBT Phase: Pooled Placebo
Number of Participants With Any Change From Baseline in Sheehan Suicidality Tracking Scale (S-STS) Scores: DBT Phase00
SecondaryNumber of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities: DBT Phase

ECG abnormalities included were a Corrected QT interval exceeding 470 milliseconds (QTc calculated using the Frederica method), left bundle branch block, right bundle branch block with a QRS duration of 150 milliseconds or more, and intraventricular conduction defect with a QRS duration equal to or greater than 150 milliseconds. Clinical significance in ECG abnormalities was judged by investigator.

Time frame:
DBT Phase: Day 1 of dosing up to last day of dosing (up to 5 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities: DBT Phase
ParticipantsDBT Phase: Pooled RimegepantDBT Phase: Pooled Placebo
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities: DBT Phase00
SecondaryNumber of Participants With Clinically Significant Laboratory Abnormalities: DBT Phase

Laboratory abnormalities included 1)Hematology: hemoglobin, hematocrit, platelets, complete blood count with differential and absolute neutrophil count; 2)Serum chemistry: sodium, potassium, chloride, calcium, alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, alkaline phosphatase, gamma-glutamyl transferase, phosphorus, bicarbonate, creatine phosphokinase, total protein, albumin, total bilirubin, glucose, creatinine, blood urea nitrogen, uric acid, total cholesterol, low-density lipoprotein, high-density lipoprotein, triglycerides, folate, hemoglobin A1C, pancreatic amylase or lipase, thyroid-stimulating Hormone, thyroxine; 3)Urinalysis: macroscopic examination, pH, specific gravity, ketones, nitrites, urobilinogen, leukocyte esterase, protein, glucose, occult blood; 4)Liver function tests: alanine aminotransferase, aspartate aminotransferase, total bilirubin, alkaline phosphatase. Clinical significance in laboratory abnormalities was judged by investigator.

Time frame:
DBT Phase: Day 1 of dosing up to last day of dosing (up to 5 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Laboratory Abnormalities: DBT Phase
ParticipantsDBT Phase: Pooled RimegepantDBT Phase: Pooled Placebo
Number of Participants With Clinically Significant Laboratory Abnormalities: DBT Phase00
SecondaryChange From Baseline in Penn Facial Pain Scale-Revised (Penn-FPS-R) Total Score at 2 Week Treatment Phase: DBT Phase

Penn-FPS-R: a 12-item scale, utilized to evaluate the impact of TN pain on health-related quality of life and daily activities. Each 12 items ranged from 0 (does not interfere) to 10 (completely interferes). Penn-FPS-R total score was calculated by adding scores of all items and had a score range of (does not interfere) 0 to 120 (completely interferes).Higher Penn-FPS-R total scores signifies worse condition. Participants were asked to complete the Penn-FPS-R at the beginning and end of each treatment period. Average of total Penn-FPS-score according to treatment received in first or second treatment period of DBT phase are used in evaluation of the outcome measure.

Time frame:
DBT Phase: Baseline, 2 Weeks Treatment
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Penn Facial Pain Scale-Revised (Penn-FPS-R) Total Score at 2 Week Treatment Phase: DBT Phase
Units on a scaleDBT Phase: Pooled RimegepantDBT Phase: Pooled Placebo
Change From Baseline in Penn Facial Pain Scale-Revised (Penn-FPS-R) Total Score at 2 Week Treatment Phase: DBT Phase-14.2 (-22.2 to -6.2)-16.6 (-24.6 to -8.6)
Statistical analysis
  • DBT Phase: Pooled Rimegepant vs DBT Phase: Pooled Placebo · Ls mean difference: 2.4 · 95% CI -6.8 to 11.5
SecondaryChange From Baseline in Pain Disability Index Total Score at 2 Week Treatment Phase: DBT Phase

Pain disability index measures the extent of disruption in a participant's daily life caused by pain, utilizing a 7-item scale scored on an 11-point Likert Scale, where "0" denotes "no disability," and "10" indicates "worst disability". Higher scores signify worse outcome. Pain disability index total score was calculated by adding scores of all the 7 items and had a score range of 0 to 70. Higher pain disability index total scores signifies worse condition. Participants were instructed to complete the pain disability index at the beginning and end of each treatment period. Average of pain disability index total scores according to treatment received in first or second treatment period of DBT phase are used for evaluation of the outcome measure.

Time frame:
DBT Phase: Baseline, 2 Weeks Treatment
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Pain Disability Index Total Score at 2 Week Treatment Phase: DBT Phase
Units on a scaleDBT Phase: Pooled RimegepantDBT Phase: Pooled Placebo
Change From Baseline in Pain Disability Index Total Score at 2 Week Treatment Phase: DBT Phase-7.8 (-12.6 to -2.9)-9.3 (-14.2 to -4.5)
Statistical analysis
  • DBT Phase: Pooled Rimegepant vs DBT Phase: Pooled Placebo · Ls mean difference: 1.5 · 95% CI -3.8 to 6.9
SecondaryPatient Global Impression of Change Scale (PGI-C) Score at 2 Week Treatment Phase: DBT Phase

PGI-C is a participant-reported scale utilized to evaluate the improvement or deterioration of the participant's current illness status compared to the baseline visit. Participants were asked to rate a change in their overall disease condition on a 7-point scale, ranging from 1 (no change) to 7 (a great deal better). Higher PGI-C scores signify better outcome. PGI-C assessments were conducted at the beginning and end of each treatment phase. Average of PGI-C score according to treatment received in first or second treatment period of DBT phase are used in evaluation of the outcome measure.

Time frame:
DBT Phase: Baseline, 2 Weeks Treatment
Reported as:
Least squares mean · Units on a scale
Patient Global Impression of Change Scale (PGI-C) Score at 2 Week Treatment Phase: DBT Phase
Units on a scaleDBT Phase: Pooled RimegepantDBT Phase: Pooled Placebo
Patient Global Impression of Change Scale (PGI-C) Score at 2 Week Treatment Phase: DBT Phase3.0 (2.3 to 3.8)3.1 (2.4 to 3.8)
Statistical analysis
  • DBT Phase: Pooled Rimegepant vs DBT Phase: Pooled Placebo · Ls mean difference: -0.1 · 95% CI -0.7 to 0.5
SecondaryChange From Baseline in Average Worst Pain Score on NPRS at 2 Week Treatment Phase: DBT Phase

NPRS is an 11-point scale ranging from 0 (no pain) to 10 (worst pain imaginable), higher scores represent worse pain. Participants daily recorded their worst pain rating over a 24-hour period on NPRS. Average of worst pain NPRS score according to treatment received in first or second treatment period of DBT phase are used in evaluation of the outcome measure.

Time frame:
DBT Phase: Baseline, 2 Weeks Treatment
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Average Worst Pain Score on NPRS at 2 Week Treatment Phase: DBT Phase
Units on a scaleDBT Phase: Pooled RimegepantDBT Phase: Pooled Placebo
Change From Baseline in Average Worst Pain Score on NPRS at 2 Week Treatment Phase: DBT Phase-0.6 (-1.3 to 0.1)-1.3 (-2.0 to -0.6)
Statistical analysis
  • DBT Phase: Pooled Rimegepant vs DBT Phase: Pooled Placebo · Ls mean difference: 0.7 · 95% CI 0.1 to 1.4
SecondaryPercentage of Participants With >= 2 Point Reduction From Baseline in Average Daily Pain Score on NPRS at 2 Week Treatment Phase: DBT Phase

NPRS is an 11-point scale ranging from 0 (no pain) to 10 (worst pain imaginable), higher scores represent worse pain. Participants daily recorded their average pain level over a 24-hour period. Pain score was the average of the daily 11-point NPRS recorded within each period. Average of pain score on NPRS according to treatment received in first or second treatment period of DBT Phase are used in evaluation of the outcome measure.

Time frame:
DBT Phase: Baseline, 2 Weeks Treatment
Reported as:
Number · Percentage of participants
Percentage of Participants With >= 2 Point Reduction From Baseline in Average Daily Pain Score on NPRS at 2 Week Treatment Phase: DBT Phase
Percentage of participantsDBT Phase: Pooled RimegepantDBT Phase: Pooled Placebo
Percentage of Participants With >= 2 Point Reduction From Baseline in Average Daily Pain Score on NPRS at 2 Week Treatment Phase: DBT Phase10.735.7
Statistical analysis
  • DBT Phase: Pooled Rimegepant vs DBT Phase: Pooled Placebo · Odds ratio (or): 12.6 · 95% CI 0.7 to 229.6

Adverse events

Collected over Day 1 up to 2 weeks of follow up post-last dose in the study (Maximum up to 19 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DBT Phase/ Treatment Sequence 1/ Period 1: Placebo0/15 (0%)0/15 (0%)1/15 (6.7%)
DBT Phase/ Treatment Sequence 1/ Period 2: Rimegepant0/14 (0%)0/14 (0%)3/14 (21.4%)
DBT Phase/ Treatment Sequence 2/ Period 1: Rimegepant0/14 (0%)0/14 (0%)3/14 (21.4%)
DBT Phase/ Treatment Sequence 2/ Period 2: Placebo0/14 (0%)0/14 (0%)0/14 (0%)
DBT Phase: Pooled Rimegepant0/28 (0%)0/28 (0%)6/28 (21.4%)
DBT Phase: Pooled Placebo0/29 (0%)0/29 (0%)1/29 (3.4%)
OLE Phase: Rimegepant0/13 (0%)0/13 (0%)4/13 (30.8%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventDBT Phase/ Treatment Sequence 1/ Period 1: PlaceboDBT Phase/ Treatment Sequence 1/ Period 2: RimegepantDBT Phase/ Treatment Sequence 2/ Period 1: RimegepantDBT Phase/ Treatment Sequence 2/ Period 2: PlaceboDBT Phase: Pooled RimegepantDBT Phase: Pooled PlaceboOLE Phase: Rimegepant
Trigeminal neuralgiaNervous system disorders0/151/142/140/143/280/293/13
ArthralgiaMusculoskeletal and connective tissue disorders0/150/140/140/140/280/291/13
Musculoskeletal chest painMusculoskeletal and connective tissue disorders0/150/140/140/140/280/291/13
FallInjury, poisoning and procedural complications0/150/140/140/140/280/291/13
Abdominal painGastrointestinal disorders0/151/140/140/141/280/290/13
Abdominal tendernessGastrointestinal disorders0/151/140/140/141/280/290/13
DizzinessNervous system disorders0/150/141/140/141/280/290/13
COVID-19Infections and infestations0/150/141/140/141/280/290/13
DepressionPsychiatric disorders0/151/140/140/141/280/290/13
DiarrhoeaGastrointestinal disorders1/150/140/140/140/281/290/13

Baseline characteristics

Participants who received at least 1 dose of double-blind study drug in DBT phase and OLE phase. Participants in DBT and OLE phases are not exclusive. Eligible participants from DBT phase entered OLE phase after completing treatment in DBT phase.

Age, Continuous
Age, Continuous(Years)DBT: Placebo Then RimegepantDBT Phase: Rimegepant Then PlaceboOLE Phase: RimegepantTotal
DBT Phase57.9 ± 13.0566.2 ± 14.61—61.9 ± 14.21
OLE Phase——61.8 ± 17.8361.8 ± 17.83
Sex: Female, Male
Sex: Female, Male(Participants)DBT: Placebo Then RimegepantDBT Phase: Rimegepant Then PlaceboOLE Phase: RimegepantTotal
DBT Phase — Female1110—21
DBT Phase — Male44—8
OLE Phase — Female——1010
OLE Phase — Male——33
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DBT: Placebo Then RimegepantDBT Phase: Rimegepant Then PlaceboOLE Phase: RimegepantTotal
DBT Phase — Hispanic or Latino34—7
DBT Phase — Not Hispanic or Latino1210—22
DBT Phase — Unknown or Not Reported00—0
OLE Phase — Hispanic or Latino——55
OLE Phase — Not Hispanic or Latino——88
OLE Phase — Unknown or Not Reported——00
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DBT: Placebo Then RimegepantDBT Phase: Rimegepant Then PlaceboOLE Phase: RimegepantTotal
DBT Phase — American Indian or Alaska Native00—0
DBT Phase — Asian00—0
DBT Phase — Native Hawaiian or Other Pacific Islander00—0
DBT Phase — Black or African American31—4
DBT Phase — White1212—24
DBT Phase — More than one race00—0
DBT Phase — Unknown or Not Reported01—1
OLE Phase — American Indian or Alaska Native——00
OLE Phase — Asian——00
OLE Phase — Native Hawaiian or Other Pacific Islander——00
OLE Phase — Black or African American——22
OLE Phase — White——1010
OLE Phase — More than one race——00
OLE Phase — Unknown or Not Reported——11
08

Study locations

20 sites
  • Gilbert Neurology Partners, PLLC/CCT Research
    Gilbert, Arizona 85297, United States
  • Center for Neurohealth DBA Kaizen Brain Center
    La Jolla, California 92037, United States
  • Imaging Clinic at Stanford Neuroscience Health Center
    Palo Alto, California 94304, United States
  • Stanford Hoover Pavilion
    Palo Alto, California 94304, United States
  • Stanford Neuroscience Health Center- SNHC Pharmacy
    Palo Alto, California 94304, United States
  • Stanford Neuroscience Health Center
    Palo Alto, California 94304, United States
  • Stanford University- CAM Building
    Stanford, California 94305, United States
  • SouthCoast Research Center
    Miami, Florida 33136, United States
  • Ochsner Baptist Medical Center
    New Orleans, Louisiana 70115, United States
  • Johns Hopkins Clinical Outpatient Center
    Baltimore, Maryland 21287, United States
  • Johns Hopkins ICTR Clinical Research Unit (CRU)
    Baltimore, Maryland 21287, United States
  • Clinical Research Professionals
    Chesterfield, Missouri 63005, United States
  • Dent Neurosciences Research Center
    Amherst, New York 14226, United States
  • Neurological Surgery Practice of Long Island PLCC
    Lake Success, New York 11042, United States
  • Neurological Surgery
    Lake Success, New York 11042, United States
  • Premier Cardiolog Consultants
    Lake Success, New York 11042, United States
  • Premier Cardiolog Consultants
    New Hyde Park, New York 11042, United States
  • Premier Cardiology Consultants
    New Hyde Park, New York 11042, United States
  • North Suffolk Neurology, PC
    Port Jefferson Station, New York 11776, United States
  • Neurology Diagnostics Inc.
    Dayton, Ohio 45459, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in May 2023, 46 months.

Results were first posted in Jun 2024, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2019
First posted
May 8, 2019
StartActual
Jun 25, 2019
Primary completionActual
May 11, 2023
CompletionActual
May 11, 2023
Results first posted
Jun 10, 2024
Last update
Jun 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03941834
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 8, 2019
Start date
Jun 25, 2019
Primary completion
May 11, 2023
Completion
May 11, 2023
Results posted
Jun 10, 2024
Last update
Jun 10, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rimegepant

Start the discussion